Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 3/20 | 0.40 |
| ▸ | ALK | Q9UM73 | 9/20 | 0.40 |
| ▸ | INSR | P06213 | 2/20 | 0.40 |
| ▸ | EGFR | P00533 | 2/20 | 0.39 |
| ▸ | MAP4K1 | Q92918 | 3/20 | 0.38 |
| ▸ | PKMYT1 | Q99640 | 1/20 | 0.38 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.37 |
| ▸ | JAK3 | P52333 | 1/20 | 0.37 |
| ▸ | SYK | P43405 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24620361 | 0.86 | MAP4K1 (0.53) | MAP4K1 | |
| SCHEMBL24620591 | 0.79 | MAP4K1 (0.46) | BTKALKMAP4K1 | |
| SCHEMBL24620202 | 0.76 | MAP4K1 (0.41) | BTKALKINSREGFRMAP4K1 | |
| SCHEMBL24620485 | 0.72 | BTK (0.47) | BTKALKMAP4K1 | |
| SCHEMBL24620259 | 0.72 | JAK3 (0.35) | BTKALKINSREGFRPKMYT1 | |
| SCHEMBL24620219 | 0.71 | JAK3 (0.34) | BTKALKINSREGFRPKMYT1 | |
| SCHEMBL18778427 | 0.70 | BTK (0.64) | BTKEGFRJAK3 | |
| SCHEMBL23764773 | 0.64 | MET (0.67) | BTKALKINSRPKMYT1 | |
| Pyrrolidine SCHEMBL613642 | 0.64 | OPRM1 (0.37) | — | |
| SCHEMBL23764832 | 0.62 | MET (0.67) | BTKALKINSRPKMYT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022147622-A1 | ISOINDOLINONE AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF NUAK KINASES, COMPOSITIONS AND USES THEREOF | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2022-07-14 | — | — | WO | disclosed |